In an 84‑year‑old patient with myelodysplastic syndrome, should I opt for supportive care only or initiate disease‑modifying treatment such as azacitidine?

Treatment Decision for 84-Year-Old with MDS

In an 84-year-old patient with myelodysplastic syndrome, the decision between supportive care and azacitidine depends critically on disease risk stratification and the presence of major comorbidities—azacitidine is recommended for higher-risk MDS patients without major comorbidities, while supportive care is appropriate for lower-risk disease or patients with significant comorbidities that would compromise treatment tolerance.

Risk Stratification is the Critical First Step

The ESMO guidelines 1 and NCCN guidelines 2 both emphasize that treatment decisions must be based on IPSS (International Prognostic Scoring System) or IPSS-R risk categories:

• Higher-risk MDS (IPSS intermediate-2 or high risk): Azacitidine is the standard of care
• Lower-risk MDS (IPSS low or intermediate-1): Supportive care with targeted interventions for specific cytopenias

For Higher-Risk MDS Without Major Comorbidities

Azacitidine is strongly recommended 1. The FDA label 3 demonstrates that azacitidine at 75 mg/m² subcutaneously daily for 7 days every 4 weeks showed superior outcomes compared to observation alone in the pivotal trial. Key findings:

• Overall response rate: 60% with azacitidine vs. minimal response with observation
• Survival benefit demonstrated even in patients over 75 years 4
• Quality of life improvements documented 2

Critical implementation points:

• Minimum 4-6 cycles required before assessing response 3
• Response may be delayed—aggressive supportive care (antiemetics, prophylactic antibiotics, transfusions) needed during initial cycles 5
• Continue treatment as long as patient benefits 3

Age Alone Should Not Exclude Treatment

The evidence specifically addresses elderly patients. Studies show azacitidine can be used safely in patients over 75 years 4 and even in the oldest MDS patients 5. The mean age in the pivotal FDA trial was 67-68 years with a range extending to 92 years 3.

When to Choose Supportive Care Only

Supportive care is appropriate when:

1. Lower-risk MDS (IPSS low or intermediate-1): These patients should receive targeted supportive interventions rather than azacitidine:

   • Erythropoiesis-stimulating agents (ESAs) for anemia 1
   • Lenalidomide for del(5q) with transfusion-dependent anemia 1
   • Iron chelation if heavily transfused 1

2. Major comorbidities present: The guidelines explicitly state azacitidine is for patients "without major comorbidities" 1. At age 84, assess:

   • Severe cardiac dysfunction
   • Advanced renal failure (contraindication for some supportive agents) 1
   • Poor performance status
   • Limited life expectancy from non-MDS causes

3. Patient preference: After informed discussion about treatment burden (7 consecutive days of injections monthly, potential for prolonged cytopenias requiring transfusions)

Common Pitfalls to Avoid

Do not stop azacitidine prematurely. The most critical error is discontinuing treatment before 4-6 cycles 3. Response is often delayed, and patients may need intensive supportive care during initial cycles before benefit emerges 5.

Avoid treatment delays during first cycles. Data shows delays during the first two treatment cycles independently worsen survival (HR 1.368, p=0.033) 6. Even in neutropenic patients, maintaining the schedule is important 6. After achieving response, delays have less impact.

Do not use 5-day regimens expecting equivalent outcomes. While 5-day azacitidine schedules exist, survival benefit has only been demonstrated with the 7-day schedule 2. The 5-day regimen showed lower cytogenetic response rates 7.

The Decision Algorithm

1. Determine IPSS risk category (requires bone marrow biopsy with cytogenetics, blast percentage, and cytopenias assessment)

2. If higher-risk (intermediate-2 or high):

   • Assess for major comorbidities
   • If no major comorbidities → Initiate azacitidine 1
   • If major comorbidities → Supportive care

3. If lower-risk (low or intermediate-1):

   • Supportive care with targeted interventions 1
   • Consider azacitidine only if progression occurs

4. For patients starting azacitidine:

   • Commit to minimum 4-6 cycles
   • Provide aggressive supportive care during initial cycles
   • Maintain schedule adherence, especially in first 2 cycles
   • Continue if responding

The evidence strongly supports disease-modifying treatment with azacitidine in higher-risk MDS even at age 84, provided comorbidities do not preclude safe administration. Age alone is not a contraindication 4, 5.